NO942912D0 - - Google Patents

Info

Publication number
NO942912D0
NO942912D0 NO942912A NO942912A NO942912D0 NO 942912 D0 NO942912 D0 NO 942912D0 NO 942912 A NO942912 A NO 942912A NO 942912 A NO942912 A NO 942912A NO 942912 D0 NO942912 D0 NO 942912D0
Authority
NO
Norway
Application number
NO942912A
Other languages
Norwegian (no)
Other versions
NO942912L (no
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO942912D0 publication Critical patent/NO942912D0/no
Publication of NO942912L publication Critical patent/NO942912L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO942912A 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 NO942912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06
PCT/US1993/000759 WO1993016184A1 (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (2)

Publication Number Publication Date
NO942912D0 true NO942912D0 (es) 1994-08-05
NO942912L NO942912L (no) 1994-10-06

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942912A NO942912L (no) 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (es)
EP (1) EP0625201A1 (es)
JP (2) JPH07505767A (es)
KR (2) KR0150060B1 (es)
CN (1) CN1077991A (es)
AR (1) AR248044A1 (es)
AU (1) AU683836B2 (es)
CA (1) CA2129445A1 (es)
CZ (1) CZ291039B6 (es)
FI (1) FI943635A0 (es)
HU (1) HUT67943A (es)
IL (1) IL104620A (es)
NO (1) NO942912L (es)
NZ (1) NZ249633A (es)
PL (1) PL176393B1 (es)
RU (1) RU94045919A (es)
SG (1) SG49597A1 (es)
SK (1) SK280610B6 (es)
TN (1) TNSN93012A1 (es)
WO (1) WO1993016184A1 (es)
ZA (1) ZA93779B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625201A1 (en) 1992-02-06 1994-11-23 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
NZ301916A (en) * 1994-12-23 1999-05-28 Smithkline Beecham Corp Monoclonal antibodies to il-5 for use as antagonists to il-5 related disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
CA2868618C (en) * 2002-10-16 2017-05-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2005297803B2 (en) 2004-10-28 2011-06-16 Kyowa Hakko Kirin Co., Ltd. Remedy for endometriosis
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ES2492943T3 (es) 2007-04-30 2014-09-10 Glaxosmithkline Llc Procedimientos de administración de anticuerpos anti-IL5
BRPI0910854A2 (pt) 2008-03-28 2015-10-06 Glaxosmithkline Llc métodos de tratamento
KR20110074879A (ko) * 2008-10-23 2011-07-04 에프. 호프만-라 로슈 아게 면역글로불린을 암호화하는 핵산의 측정 방법
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
CN107073114B (zh) 2014-09-08 2022-01-14 赛福伦公司 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
AU2016311385C1 (en) 2015-08-24 2019-08-22 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌcd20モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
CA3076941A1 (en) * 2017-09-29 2019-04-04 Jiangsu Hengrui Medicine Co., Ltd. Il-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业(上海)股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ATE98872T1 (de) * 1988-11-03 1994-01-15 Schering Corp Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
EP0625201A1 (en) 1992-02-06 1994-11-23 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
AU3656093A (en) 1993-09-03
SK91894A3 (en) 1995-02-08
WO1993016184A1 (en) 1993-08-19
CZ291039B6 (cs) 2002-12-11
EP0625201A1 (en) 1994-11-23
IL104620A0 (en) 1993-06-10
PL176393B1 (pl) 1999-05-31
HUT67943A (en) 1995-05-29
NZ249633A (en) 1995-12-21
SK280610B6 (sk) 2000-05-16
CA2129445A1 (en) 1993-08-07
KR950700413A (ko) 1995-01-16
US6451982B1 (en) 2002-09-17
KR0150060B1 (ko) 1998-08-17
AR248044A1 (es) 1995-05-31
CN1077991A (zh) 1993-11-03
IL104620A (en) 2000-02-29
AU683836B2 (en) 1997-11-27
RU94045919A (ru) 1996-11-10
FI943635A (fi) 1994-08-05
SG49597A1 (en) 1998-06-15
JPH07505767A (ja) 1995-06-29
HU9402293D0 (en) 1994-10-28
TNSN93012A1 (fr) 1994-03-17
JP2000210097A (ja) 2000-08-02
ZA93779B (en) 1993-08-05
CZ191094A3 (en) 1994-12-15
NO942912L (no) 1994-10-06
FI943635A0 (fi) 1994-08-05

Similar Documents

Publication Publication Date Title
DK0613608T3 (es)
NO942912D0 (es)
DK0553875T3 (es)
DK0596750T3 (es)
DK0554977T3 (es)
DK0632741T3 (es)
DK0625187T3 (es)
DK0576346T3 (es)
DK0571874T3 (es)
DK0574276T3 (es)
DK0596569T3 (es)
DK0581726T3 (es)
TW265354B (es)
DE9207553U1 (es)
FR2687859B1 (es)
AU631518B2 (es)
IN185185B (es)
BRPI9204323A2 (es)
IN185201B (es)
IN181101B (es)
IN176654B (es)
AU1117992A (es)
AU1809592A (es)
AU1812892A (es)
AU1862992A (es)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application